Evolving refractory major depressive disorder diagnostic and treatment paradigms: toward closed-loop therapeutics
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Current antidepressant therapies do not effectively control or cure depressive symptoms. Pharmaceutical therapies altogether fail to address an estimated 4 million Americans who suffer from a recurrent and severe treatment-resistant form of depression known as refractory major depressive disorder. Subjective diagnostic schemes, differing manifestations of the disorder, and antidepressant treatments with limited theoretical bases each contribute to the general lack of therapeutic efficacy and differing levels of treatment resistance in the refractory population. Stimulation-based therapies, such as vagus nerve stimulation, transcranial magnetic stimulation, and deep brain stimulation, are promising treatment alternatives for this treatment-resistant subset of patients, but are plagued with inconsistent reports of efficacy and variable side effects. Many of these problems stem from the unknown mechanisms of depressive disorder pathogenesis, which prevents the development of treatments that target the specific underlying causes of the disorder. Other problems likely arise due to the non-specific stimulation of various limbic and paralimbic structures in an open-loop configuration. This review critically assesses current literature on depressive disorder diagnostic methodologies, treatment schemes, and pathogenesis in order to emphasize the need for more stringent depressive disorder classifications, quantifiable biological markers that are suitable for objective diagnoses, and alternative closed-loop treatment options tailored to well-defined forms of the disorder. A closed-loop neurostimulation device design framework is proposed, utilizing symptom-linked biomarker abnormalities as control points for initiating and terminating a corrective electrical stimulus which is autonomously optimized for correcting the magnitude and direction of observed biomarker abnormality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Genetic Epidemiology of Major Depression: Review and Meta-Analysis
Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.10.1552 · Cited by 3,431 · cited 2×
“…heritability studies, it is clear that genetics and environmental factors (i.e., nature and nurture) play synergistic roles in individual susceptibility to developing the disorder (Heils et al., 1996; Sullivan et al., 2000; Caspi et al., 2003; Kendler et al., 2005; Bradley et al., 2008).”
Pascual-Marqui, R. D., Michel, C. M., & Lehmann, D. (1994) · International Journal of Psychophysiology · doi:10.1016/0167-8760(84)90014-x · Cited by 2,869
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Allelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
Belmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Glucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders
Sapolsky, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.925 · Cited by 2,016
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795 · cited 5×
“, Antidepressants work to lower stress levels and increase BDNF availability, thereby allowing natural repair mechanisms to correct functional deficits and ultimately reduce symptoms) (Duman and Monteggia, 2006; Pittenger and Duman, 2008).”
InfluentialLimbic-cortical dysregulation: a proposed model of depression
(1997) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.9.3.471 · Cited by 1,585 · cited 1×
“These depressed states are brought about by an underlying “system-level disorder affecting discrete, but functionally integrated (biological) pathways” (Mayberg, 1997).”
Nemeroff, C. B., Widerlöv, E., Bissette, G., Walléus, H., Karlsson, I., Eklund, K., Kilts, C. D., Loosen, P. T., & Vale, W. (1984) · Science · doi:10.1126/science.6334362 · Cited by 1,485 · cited 1×
“Observations leading to and strengthening this theory are: (1) elevated CRH and cortisol levels were observed in the cerebrospinal fluid (Nemeroff et al., 1984; Merali et al., 2004) and plasma (Burke et al., 2005) of depressed patients, respectively; (2) higher levels of cortisol and ACTH…”
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 4×
“Since antidepressant therapies do not have well-defined targets, proven mechanisms of action, and consistent reports of clinical efficacy, it is no surprise that varying levels of treatment resistance are consistently reported (Thase and Rush, 1997; Fava, 2003; Mann, 2005; Belmaker and Agam, 2008; Kirsch et al., 2008).”
InfluentialDecreased serum brain-derived neurotrophic factor levels in major depressed patients
Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., & Aubry, J.-M. (2002) · Psychiatry Research · doi:10.1016/s0165-1781(02)00005-7 · Cited by 1,232
The Biochemistry of Affective Disorders
Coppen, A. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1237 · Cited by 1,230 · cited 2×
“MonoaMIne-defIcIency hypothesIs The dominant hypothesis from 1967 until well into the 1990s was the monoamine-deficiency hypothesis of depression, a hypothesis implicating dysfunctional serotonin, norepinephrine, and dopamine systems in depressive disorder pathogenesis (Coppen, 1967).”
Depression and cortisol responses to psychological stress: A meta-analysis
Burke, H. M., Davis, M. C., Otte, C., & Mohr, D. C. (2005) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.02.010 · Cited by 1,194
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 2×
“…Neuroengineering www.frontiersin.org May 2010 | Volume 3 | Article 7 | 1 NEUROENGINEERING Review ARticle published: 31 May 2010 doi: 10.3389/fneng.2010.00007 persists for up to a year (Judd et al., 1998), significantly impairing the health and daily activities of the afflicted (Manji et al., 2001).”
InfluentialShimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., Nakazato, M., Watanabe, H., Shinoda, N., Okada, S.-I., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00181-1 · Cited by 1,151 · cited 2×
“, 2005) and decreased BDNF levels (Shimizu et al., 2003) are among the most promising biomarkers of depression, decreased folate in blood serum is among the most promising biomarkers of treatment resistance (Fava et al.”
Depression: Perspectives from Affective Neuroscience
Davidson, R. J., Pizzagalli, D., Nitschke, J. B., & Putnam, K. (2002) · Annual Review of Psychology · doi:10.1146/annurev.psych.53.100901.135148 · Cited by 1,138
Mayberg, H. S., Brannan, S. K., Tekell, J. L., Silva, J. A., Mahurin, R. K., McGinnis, S., & Jerabek, P. A. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01036-2 · Cited by 1,115 · cited 8×
“Pulse width, amplitude, pulse train duration, and/or pulse repetition frequency is varied for the next SCGwm stimulation based on the type of biomarker abnormality detected and previous stimulus/biomarker response data (this data is represented as a multidimensional stimulus response surface).”
InfluentialGoldapple, K., Segal, Z., Garson, C., Lau, M., Bieling, P., Kennedy, S., & Mayberg, H. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.34 · Cited by 1,068
Adult brain neurogenesis and psychiatry: a novel theory of depression
Jacobs, B. L., van Praag, H., & Gage, F. H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000712 · Cited by 964
The macrophage theory of depression
Smith, R. S. (1991) · Medical Hypotheses · doi:10.1016/0306-9877(91)90272-z · Cited by 931 · cited 3×
“…disorders, such as rheumatoid arthritis or heart disease, involve significant macrophage activation (possibly as a result of chronic inflammatory effects, Dantzer et al., 2008) (Smith, 1991); and (5) Yirmiya et al. (2000) showed that antidepressants can alleviate the symptoms of sickness behavior.”
Recurrence after recovery from major depressive disorder during 15 years of observational follow-up
Mueller, T. I., Leon, A. C., Keller, M. B., Solomon, D. A., Endicott, J., Coryell, W., Warshaw, M., & Maser, J. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1000 · Cited by 897 · cited 1×
“Even with the best FDA-approved antidepressant treatments, the majority of MDD patients will inevitably suffer from multiple depressive episodes during their lifetime(Mueller et al., 1999; Kessler et al., 2003).”
Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression
Malone, D. A., Dougherty, D. D., Rezai, A. R., Carpenter, L. L., Friehs, G. M., Eskandar, E. N., Rauch, S. L., Rasmussen, S. A., Machado, A. G., Kubu, C. S., et al. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.029 · Cited by 897 · cited 1×
“…target deep structures such as the subcallosal cingulate gyrus (SCG) (Mayberg et al., 2000, 2005; Lozano et al., 2008), ventral capsule/ventral striatum (VC/VS) (Malone et al., 2009), globus pallidus internus (GPi) (Kosel et al., 2007), and inferior thalamic peduncle (ITP) (Jimenez et al., 2005).”
Ruhé, H. G., Mason, N. S., & Schene, A. H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001949 · Cited by 861
Multiple recurrences of major depressive disorder
Solomon, D. A., Keller, M. B., Leon, A. C., Mueller, T. I., Lavori, P. W., Shea, M. T., Coryell, W., Warshaw, M., Turvey, C., Maser, J. D., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.2.229 · Cited by 835 · cited 1×
“To make matters worse, each recurrent depressive episode puts the patient at a 16% increased risk for developing an additional depressive episode during their lifetime (Solomon et al., 2000).”
Judd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.8.694 · Cited by 775
Ben‐Menachem, E., Mañon‐Espaillat, R., Ristanovic, R., Wilder, B. J., Stefan, H., Mirza, W., Tarver, W. B., Wernicke, J. F., & First International Vagus Nerve Stimulation Study Group (1994) · Epilepsia · doi:10.1111/j.1528-1157.1994.tb02482.x · Cited by 683 · cited 2×
“…refractory MDD originated from unexpected patientreported mood improvements observed in the NeuroCybernetic Prosthesis System trials in the 1990s (Ben-Menachem et al., 1994) and the off-label uses of specific seizure medications for stabilizing mood disorders (Ballenger and Post, 1980; Post et…”
Neuronal plasticity and survival in mood disorders
Duman, R. S., Malberg, J., Nakagawa, S., & D’Sa, C. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00935-5 · Cited by 652
Pizzagalli, D., Pascual-Marqui, R. D., Nitschke, J. B., Oakes, T. R., Larson, C. L., Abercrombie, H. C., Schaefer, S. M., Koger, J. V., Benca, R. M., & Davidson, R. J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.405 · Cited by 630 · cited 4×
“…dose of charge and its rate of delivery, using electrical stemming from the limitations of using low bandwidth electroencephalograms (EEG) (Pizzagalli et al., 2001) or evoked response field potentials (Garrett et al., 2008) to investigate disorders of specific neural circuits in deeper…”
InfluentialNemeroff, C. B., Mayberg, H. S., Krahl, S. E., McNamara, J., Frazer, A., Henry, T. R., George, M. S., Charney, D. S., & Brannan, S. K. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301082 · Cited by 496 · cited 1×
“FDA approval followed in July, 2005 (George et al., 2000; Nemeroff et al., 2006).”
Vagus nerve stimulation: a new tool for brain research and therapy
George, M. S., Sackeim, H. A., Rush, A. J., Marangell, L. B., Nahas, Z., Husain, M. M., Lisanby, S., Burt, T., Goldman, J., & Ballenger, J. C. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00308-x · Cited by 461
Serotonin and Depression: A Disconnect between the Advertisements and the Scientific Literature
Lacasse, J. R., & Leo, J. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020392 · Cited by 377 · cited 7×
“Several recent investigations and literature analyses have discredited this theory by questioning its origin, re-evaluating published and unpublished clinical efficacy data, and elucidating other actions of effective antidepressants (Lacasse and Leo, 2005; Kirsch et al., 2008; Turner et al., 2008).”
InfluentialGeorge, M. S., Rush, A. J., Marangell, L. B., Sackeim, H. A., Brannan, S. K., Davis, S. M., Howland, R., Kling, M. A., Moreno, F., Rittberg, B., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.028 · Cited by 372
Alesci, S., Martinez, P. E., Kelkar, S., Ilias, I., Ronsaville, D. S., Listwak, S. J., Ayala, A. R., Licinio, J., Gold, H. K., Kling, M. A., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1667 · Cited by 372
O’Brien, S. M., Scully, P., Fitzgerald, P., Scott, L. V., & Dinan, T. G. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.05.013 · Cited by 355
Avery, D. H., Holtzheimer, P. E., Fawaz, W., Russo, J., Neumaier, J., Dunner, D. L., Haynor, D. R., Claypoole, K. H., Wajdik, C., & Roy-Byrne, P. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.003 · Cited by 318
Pathophysiology of hypercortisolism in depression
Carroll, B. J., Cassidy, F., Naftolowitz, D., Tatham, N. E., Wilson, W. H., Iranmanesh, A., Liu, P. Y., & Veldhuis, J. D. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.00967.x · Cited by 317
Jiménez, F., Velasco, F., Salin-Pascual, R., Hernández, J. A., Velasco, M., Criales, J. L., & Nicolini, H. (2005) · Neurosurgery · doi:10.1227/01.neu.0000170434.44335.19 · Cited by 291
Folate, vitamin B12, and homocysteine in major depressive disorder
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.3.426 · Cited by 287 · cited 2×
“Transcranial magnetic and Bottiglieri, T. (1997). Folate, vitamin B12, and homocysteine in major depressive disorder.”
Illness, Cytokines, and Depression
YIRMIYA, R., POLLAK, Y., MORAG, M., REICHENBERG, A., BARAK, O., AVITSUR, R., SHAVIT, Y., OVADIA, H., WEIDENFELD, J., MORAG, A., et al. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05412.x · Cited by 284
Peretti, S., Judge, R., & Hindmarch, I. (2000) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2000.tb10944.x · Cited by 236 · cited 1×
“…refractory MDD is a lengthy process that often is not in the best interest of the patient’s health due to potentially life-threatening antidepressant side effects (e.g., violent behavior, cardiovascular problems, and/or recurrent thoughts of death/ suicide) (Peretti et al., 2000; Mann, 2005).”
McCreery, D. B., Yuen, T. G. H., Agnew, W. F., & Bullara, L. A. (1997) · IEEE Transactions on Biomedical Engineering · doi:10.1109/10.634645 · Cited by 130 · cited 1×
“…over time (e.g., long-term, high-frequency stimulation in this manner may enhance phenomena such as stimulation-induced depression of neuronal excitability, a phenomenon in which a neuron develops a tolerance to a constant stimulus by increasing its threshold for activation, McCreery et al., 1997).”
Carpenter, L. L., Moreno, F. A., Kling, M. A., Anderson, G. M., Regenold, W. T., Labiner, D. M., & Price, L. H. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.025 · Cited by 123 · cited 22×
“Additional positron-emission tomography (PET) studies showed that VNS reduced cingulate activity, the same effect seen from many successful antidepressant therapies (George et al., 2000), and altered blood flow and metabolism in limbic structures (Henry et al., 1998).”
InfluentialVelasco, F., Velasco, M., Jiménez, F., Velasco, A. L., & Salin-Pascual, R. (2005) · Neurosurgery · doi:10.1227/01.neu.0000172172.51818.51 · Cited by 75
Cited by
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
“Ward and Irazoqui have provided greater detail on target structures, motivation, response rates, and the proposed mechanism of action of somatic therapies used in treatmentresistant depression.(4) Data from a follow-up study suggested that in the long term (up to 6 years), DBS remains a safe and effective treatment fo…”
Closed-loop Neurostimulation: The Clinical Experience
Sun, F. T., & Morrell, M. J. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0280-3 · Cited by 286
Widge, A. S., Ellard, K. K., Paulk, A. C., Basu, I., Yousefi, A., Zorowitz, S., Gilmour, A., Afzal, A., Deckersbach, T., Cash, S. S., et al. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2016.07.021 · Cited by 118
Hao, C., Gao, Z., Liu, X., Rong, Z., Jia, J., Kang, K., Guo, W., & Li, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-77085-z · Cited by 43
Metadata
- Authors
- Ward, M. P.
- Venue
- Frontiers in Neuroengineering
- Publisher
- Frontiers Media SA
- Published
- 2010
- Volume
- 3
- Pages
- 7-7
- ISSN
- 1662-6443 (ISSN-L)
- OpenAlex
- W1968077576
- Cited by
- 43
- References
- 47
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.